Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority.
作者信息
Riva Nicoletta, Ageno Walter
机构信息
Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy.
出版信息
Blood Transfus. 2015 Apr;13(2):181-3. doi: 10.2450/2015.0057-15.
Abstract
摘要
相似文献
1
Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority.哪些静脉血栓栓塞患者应接受非维生素K拮抗剂口服抗凝药治疗？大多数患者。
Blood Transfus. 2015 Apr;13(2):181-3. doi: 10.2450/2015.0057-15.
2
Are New Oral Anticoagulants Safer Than Vitamin K Antagonists in the Treatment of Venous Thromboembolism?新型口服抗凝剂在治疗静脉血栓栓塞症方面是否比维生素K拮抗剂更安全？
Ann Emerg Med. 2016 Apr;67(4):455-7. doi: 10.1016/j.annemergmed.2015.08.018. Epub 2015 Oct 3.
3
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.非维生素K拮抗剂口服抗凝药在静脉血栓栓塞管理中的获益-风险概况
Thromb Haemost. 2015 Feb;113(2):231-46. doi: 10.1160/TH14-06-0484. Epub 2014 Oct 16.
4
New oral anticoagulants versus vitamin K antagonists for treatment of acute venous thromboembolism: do they really increase the incidence of myocardial infarction?新型口服抗凝剂与维生素K拮抗剂治疗急性静脉血栓栓塞症：它们真的会增加心肌梗死的发生率吗？
Intern Emerg Med. 2015 Jun;10(4):493-8. doi: 10.1007/s11739-015-1224-6. Epub 2015 Mar 29.
5
Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism.直接口服抗凝剂在静脉血栓栓塞症治疗中的应用。
Hematol Oncol Clin North Am. 2016 Oct;30(5):1035-51. doi: 10.1016/j.hoc.2016.05.008. Epub 2016 Jul 20.
6
Novel anticoagulants: a discussion of clinical use in the treatment and prevention of venous thromboembolism.新型抗凝剂：关于其在静脉血栓栓塞症治疗和预防中的临床应用探讨
Phlebology. 2011 Feb;26(1):3-7. doi: 10.1258/phleb.2010.010023.
7
Bridging therapy in oral anticoagulated patients: focusing on how to do it.口服抗凝治疗患者的桥接治疗：重点关注如何进行桥接治疗。
Intern Emerg Med. 2007 Dec;2(4):247-9. doi: 10.1007/s11739-007-0074-2.
8
Recurrent venous thromboembolism: quite harmless after all?复发性静脉血栓栓塞症：终究危害不大？
Thromb Haemost. 2008 Apr;99(4):655-6. doi: 10.1160/TH08-03-0137.
9
[New oral anticoagulants for treatment of venous thromboembolism].用于治疗静脉血栓栓塞症的新型口服抗凝剂
Dtsch Med Wochenschr. 2011 Jun;136(22):1162-4. doi: 10.1055/s-0031-1280530. Epub 2011 May 24.
10
[Bleeding during anti-vitamin K treatment. Incidence, risk factors and comparison with the new oral anticoagulants].[抗维生素K治疗期间的出血。发病率、危险因素及与新型口服抗凝剂的比较]
Medicina (B Aires). 2012;72(5):419-24.
引用本文的文献
1
Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register.在静脉血栓栓塞患者中使用直接口服抗凝剂或维生素 K 拮抗剂治疗期间的出血和血栓并发症，包括在前瞻性、观察性 START2 注册研究中。
BMJ Open. 2020 Nov 27;10(11):e040449. doi: 10.1136/bmjopen-2020-040449.
2
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.直接口服抗凝剂用于静脉血栓栓塞症的延长治疗：来自 EINSTEIN CHOICE 研究的见解。
Blood Transfus. 2020 Jan;18(1):49-57. doi: 10.2450/2019.0265-18. Epub 2019 Apr 30.
3
How we treat bleeding associated with direct oral anticoagulants.我们如何治疗与直接口服抗凝剂相关的出血。
Blood Transfus. 2016 Sep;14(5):465-73. doi: 10.2450/2016.0180-15. Epub 2016 Jan 19.
4
The evolution of anticoagulant therapy.抗凝治疗的演变
Blood Transfus. 2016 Mar;14(2):175-84. doi: 10.2450/2015.0096-15. Epub 2015 Dec 16.
5
The use of novel oral anticoagulants: the debate continues!新型口服抗凝药的应用：争论仍在继续！
Blood Transfus. 2015 Apr;13(2):170-1. doi: 10.2450/2015.0059-15.
本文引用的文献
1
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.非维生素K拮抗剂口服抗凝药在静脉血栓栓塞管理中的获益-风险概况
Thromb Haemost. 2015 Feb;113(2):231-46. doi: 10.1160/TH14-06-0484. Epub 2014 Oct 16.
2
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.2014年欧洲心脏病学会急性肺栓塞诊断和管理指南
Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k. doi: 10.1093/eurheartj/ehu283. Epub 2014 Aug 29.
3
Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.急性深静脉血栓形成和/或肺栓塞患者的治疗：特定人群中新型口服抗凝药的疗效和安全性。
Thromb Res. 2014 Aug;134(2):227-33. doi: 10.1016/j.thromres.2014.05.013. Epub 2014 May 13.
4
Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism.癌症相关急性静脉血栓栓塞症患者中新口服抗凝剂的疗效和安全性的荟萃分析。
J Thromb Haemost. 2014 Jul;12(7):1116-20. doi: 10.1111/jth.12605. Epub 2014 Jun 19.
5
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.达比加群或华法林治疗急性静脉血栓栓塞症及汇总分析。
Circulation. 2014 Feb 18;129(7):764-72. doi: 10.1161/CIRCULATIONAHA.113.004450. Epub 2013 Dec 16.
6
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.新型口服抗凝剂与维生素 K 拮抗剂治疗急性有症状静脉血栓栓塞症的有效性和安全性：系统评价和荟萃分析。
J Thromb Haemost. 2014;12(3):320-8. doi: 10.1111/jth.12485.
7
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.口服利伐沙班与标准治疗用于治疗有症状的静脉血栓栓塞症：EINSTEIN-DVT 和 PE 随机研究的汇总分析。
Thromb J. 2013 Sep 20;11(1):21. doi: 10.1186/1477-9560-11-21.
8
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.依度沙班与华法林治疗有症状的静脉血栓栓塞症。
N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31.
9
Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism.复发性血栓栓塞和大出血患者的病死率及主要出血率的变化情况。
Thromb Haemost. 2013 Oct;110(4):834-43. doi: 10.1160/TH13-02-0132. Epub 2013 Jul 11.
10
Oral apixaban for the treatment of acute venous thromboembolism.口服阿哌沙班治疗急性静脉血栓栓塞症。
N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.
Zotero 插件